Endocrinology

Your Article Summary

See Latest Articles

The effects of an olmesartan medoxomil–based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older
The Journal of Clinical Hypertension, 07/01/09

Kereiakes DJ et al. – An olmesartan medoxomil (OM)-based treatment algorithm effectively lowers blood pressure (BP) in an elderly pt population throughout 24-hr dosing interval without compromising tolerability.

• Study of the effect of OM ± hydrochlorothiazide (HCTZ) on mean 24-hr ambulatory BP, mean seated cuff (Se)BP, and SeBP goal achievement in hypertensive pts age ≥65 yrs
• After 2- to 3-wk placebo run-in, OM 20 mg, uptitrated to 40 mg, then added HCTZ 12.5 mg to 25 mg stepwise at 3-wk intervals if SeBP remained ≥120/70 mm Hg
• Primary endpoint: change from baseline in mean 24-hr ambulatory systolic BP

• At study end, mean 24-hr ambulatory BP decreased by 25.7/12.3 mm Hg (150 pts) and mean SeBP by 25.4/10.5 mm Hg (176 pts)
• Drug-related treatment-emergent adverse events, most commonly dizziness (3.4%), hypotension (2.2%), and headache (1.1%), in 11.8% of pts

Today in Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09

Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension
Journal of Human Hypertension, 11/10/09

See All of Hypertension